Valsartan mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Valsartan Mechanism of Action: Angiotensin II Receptor Blockade
Valsartan is primarily known as an angiotensin II type 1 receptor (AT1R) blocker. By selectively blocking AT1R, valsartan prevents angiotensin II from binding to its receptor, which leads to vasodilation, reduced blood pressure, and decreased aldosterone secretion. This action helps counteract the overactivation of the renin-angiotensin-aldosterone system (RAAS), which is a key driver of hypertension, vasoconstriction, and cardiac remodeling in heart failure and related cardiovascular diseases 59.
Valsartan and Nitric Oxide Production in Endothelial Cells
Valsartan also increases nitric oxide (NO) bioavailability in endothelial cells. It does this by promoting the phosphorylation of endothelial nitric oxide synthase (eNOS) through the Src/PI3K/Akt signaling pathway. This leads to increased NO production, which contributes to vasodilation and vascular protection. The process involves valsartan-induced phosphorylation of AT1R (dependent on Src), and suppression of the interaction between eNOS and AT1R, further enhancing NO release .
Cardioprotective Effects: Cardiac Remodeling and Apoptosis
Valsartan has demonstrated beneficial effects in preventing cardiac remodeling and myocardial apoptosis, especially in conditions like heart failure and diabetic cardiomyopathy. It inhibits pathways involved in cell death, such as the CHOP/Puma signaling pathway, thereby reducing endoplasmic reticulum (ER) stress-induced apoptosis in heart muscle cells. This protective effect helps preserve cardiac structure and function 18.
Antioxidant and Antiglycation Properties
Beyond its role as an AT1R blocker, valsartan exhibits antioxidant and antiglycation properties. It reduces protein oxidation and glycation, which are processes that contribute to cardiovascular disease progression. Valsartan’s ability to lower the levels of protein oxidation and glycation products, while increasing antioxidant activity, suggests an additional mechanism by which it may protect the cardiovascular system .
Regulation of Systemic Vascular Resistance and Blood Pressure
Valsartan’s antihypertensive effect is closely linked to its regulation of vasodilation and systemic vascular resistance. Mathematical modeling has shown that valsartan’s impact on blood pressure is influenced by circadian rhythms, with greater effects observed when the drug is administered at bedtime. This highlights the importance of dosing time in optimizing its antihypertensive action .
Conclusion
In summary, valsartan lowers blood pressure and protects the heart by blocking angiotensin II type 1 receptors, increasing nitric oxide production, reducing cardiac cell death, and providing antioxidant benefits. These combined mechanisms make valsartan an effective treatment for hypertension and heart failure, with additional protective effects on the cardiovascular system 1258+2 MORE.
Sources and full results
Most relevant research papers on this topic
Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
Sacubitril/Valsartan effectively prevents post-infarct remodeling by inhibiting cardiomyocyte cell death and extracellular matrix remodeling through synergistic pathways.
Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling.
Valsartan increases nitric oxide production in endothelial cells through Src/PI3K/Akt-dependent phosphorylation of eNOS, providing a novel vasoprotective mechanism.
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Sacubitril/valsartan significantly reduces mortality and hospitalization rates in heart failure patients, improving cardiac remodeling and quality of life.
In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan
TPMS technology can identify potential biomarkers for identifying individuals more prone to macular degeneration when receiving sacubitril/valsartan for heart failure treatment.
Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats.
Valsartan protects against ER stress-induced cardiac remodeling and myocardial apoptosis in diabetic rats by blocking the activation of the CHOP/Puma signaling pathway.
DOI